RLMD - NASDAQ
Relmada Therapeutics, Inc.
$6.38
-0.62%Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
At a Glance
Live Snapshotrlmd
Research Development Expenses
Last Annual Value
744.56K
3-Year CAGR
-81%
5-Year CAGR
-54%
10-Year CAGR
-19%
Relmada Therapeutics, Inc. Competitors Analysis of research-development-expenses
| Company | research-development-expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Relmada Therapeutics, Inc. NASDAQ:RLMD | 744.56K | -76.1% | -61.7% | -5.4% | |
 TScan Therapeutics, Inc. NASDAQ:TCRX | 114.15M | 9.0% | 20.5% | N/A | |
 Adicet Bio, Inc. NASDAQ:ACET | 99.13M | -2.2% | 15.2% | 32.5% | |
 Vaxart, Inc. NASDAQ:VXRT | 201.58M | 43.6% | 32.8% | 21.7% | |
 CAMP4 Therapeutics Corporation NASDAQ:CAMP | 38.20M | -2.0% | 6.1% | 5.7% | |
 Clene Inc. NASDAQ:CLNN | 14.01M | -19.3% | -13.2% | N/A | |
 Werewolf Therapeutics, Inc. NASDAQ:HOWL | 44.83M | 2.4% | 4.9% | N/A | |
 Artiva Biotherapeutics, Inc. NASDAQ:ARTV | 69.54M | 11.4% | 10.4% | N/A | |
 Precision BioSciences, Inc. NASDAQ:DTIL | 54.17M | 0.5% | -14.0% | 19.5% | |
 Prelude Therapeutics Incorporated NASDAQ:PRLD | 94.30M | -3.0% | 1.7% | N/A | |
 Sutro Biopharma, Inc. NASDAQ:STRO | 166.42M | -2.7% | 9.8% | 14.3% |
Relmada Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your RLMD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.